CURE’s thyroid cancer page is an extensive resource of cancer information featuring the latest thyroid cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on thyroid cancer.
August 25th 2023
Progression-free survival improved with Retevmo as the initial treatment for patients with advanced RET-mutant medullary thyroid cancer.
Cancer: It's Never An Easy Journey
July 2nd 2019Cancer doesn’t discriminate. It doesn’t care what race, gender, ethnicity, sexuality or even age you are. It takes no prisoners. And it certainly did not take me. I continue to remain resilient despite what I’ve been through and despite what still may be on the horizon.
LOXO-292 Granted Breakthrough Designation for Thyroid Cancer
October 15th 2018The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.
LOXO-292 Granted Breakthrough Therapy Designation for Lung and Thyroid Cancer
September 5th 2018The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.
FDA Approves Combination for Rare Thyroid Cancer Type
May 4th 2018The Food and Drug Administration (FDA) approved the two-drug combination Tafinlar (dabrafenib) and Mekinist (trametinib) to treat patients with metastatic or unresectable anaplastic thyroid cancer (ATC), whose tumors harbor the BRAF V600E mutation.